L-155-2018

Agreement ID
L-155-2018
Lead IC
NIAID
Exclusivity
Nonexclusive
External Party
AstraZeneca Ireland Ltd
Fiscal Year
2026
Territory
Worldwide
Execution Date
Effective Date
Export Date
Technologies
TAB-2717     Recombinant Stabilized Prefusion Protein of Respiratory Syncytial Virus for Use as a Subunit Vaccine
TAB-3342     Fusion Glycoprotein Vaccine for Human Metapneumovirus
TAB-3336     Substitutions-Modified Prefusion RSV F Proteins and Their Use
TAB-3429     Prefusion-Stabilized Fusion (F) Glycoprotein Vaccine Immunogens For Human Metapneumovirus